Vienna, Austria

Rosemarie Riedl

This inventor holds 7 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 11 EPO patents. Top assignees: Nabriva Therapeutics Ag, Ariva Med Gmbh. Active years: 2015-2026.

USPTO Granted Patents = 7 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 4.1

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2015-2026

Loading Chart...
Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Rosemarie Riedl

Introduction

Rosemarie Riedl is a prominent inventor based in Vienna, Austria. She has made significant contributions to the field of pharmaceuticals, particularly through her innovative patents. With a total of 7 patents, Riedl's work has had a substantial impact on medical science.

Latest Patents

Among her latest patents are the "Siderophore cephalosporin conjugates and uses thereof" and "12-epi pleuromutilins." The first patent describes a complex compound with various chemical groups that enhance its efficacy. The second patent focuses on a compound characterized by specific substitutions in the mutilin ring, which has potential applications as a pharmaceutical agent.

Career Highlights

Riedl has worked with notable companies such as Nabriva Therapeutics AG and Ariva Med GmbH. Her experience in these organizations has allowed her to develop and refine her innovative ideas, contributing to advancements in drug development.

Collaborations

Some of her notable coworkers include Werner Heilmayer and Klaus Thirring. Their collaboration has likely fostered a creative environment that encourages the development of groundbreaking inventions.

Conclusion

Rosemarie Riedl's contributions to the field of pharmaceuticals through her patents and collaborations highlight her role as an influential inventor. Her work continues to inspire advancements in medical science.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…